ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,291.34
      0.15%
      US Tech 100
      18,200.00
      0.41%
      Dow Jones
      38,711.29
      0.36%
      Brent Oil
      77.365
      0.33%
      Bitcoin
      71,010.78
      0.64%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Adagene Inc (ADAG)

      7. Adagene Inc (ADAG) News

      ADAG

      Adagene (ADAG)

      Adagene Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:ADAG
      DateTimeSourceHeadlineSymbolCompany
      1:08PMiHub NewswireFeaturedElement79 Gold Corp Continues Fostering Local Community Engagement
      05/22/20244:45PMGlobeNewswire Inc.Adagene to Present at Investor Conferences in JuneNASDAQ:ADAGAdagene Inc
      03/29/20249:00AMGlobeNewswire Inc.Adagene Reports Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:ADAGAdagene Inc
      03/07/20244:01PMGlobeNewswire Inc.Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory BoardNASDAQ:ADAGAdagene Inc
      03/01/20244:30PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ADAGAdagene Inc
      02/27/20248:00AMGlobeNewswire Inc.Adagene to Present at the Leerink Partners Global Biopharma Conference 2024NASDAQ:ADAGAdagene Inc
      02/09/20246:08AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ADAGAdagene Inc
      02/09/20246:00AMGlobeNewswire Inc.Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabNASDAQ:ADAGAdagene Inc
      01/16/20245:01PMGlobeNewswire Inc.Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)NASDAQ:ADAGAdagene Inc
      01/16/20245:00PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ADAGAdagene Inc
      01/04/20245:00AMGlobeNewswire Inc.Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI SymposiumNASDAQ:ADAGAdagene Inc
      11/03/202312:00PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ADAGAdagene Inc
      11/03/202312:00PMGlobeNewswire Inc.Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023NASDAQ:ADAGAdagene Inc
      10/12/20238:00AMGlobeNewswire Inc.Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingNASDAQ:ADAGAdagene Inc
      09/29/20236:30AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ADAGAdagene Inc
      09/07/20236:00AMGlobeNewswire Inc.Adagene to Present at Investor and Scientific Conferences in SeptemberNASDAQ:ADAGAdagene Inc
      08/31/20237:32AMGlobeNewswire Inc.Adagene Reports Six Month Financial Results for 2023 and Provides Corporate UpdateNASDAQ:ADAGAdagene Inc
      08/31/20237:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ADAGAdagene Inc
      07/07/20234:34PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ADAGAdagene Inc
      05/04/20239:01AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ADAGAdagene Inc
      05/04/20239:00AMGlobeNewswire Inc.Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug ConjugateNASDAQ:ADAGAdagene Inc
      04/28/20237:06AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ADAGAdagene Inc
      04/28/20237:03AMEdgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:ADAGAdagene Inc
      04/28/20237:00AMGlobeNewswire Inc.Adagene Announces Updates to its Board of DirectorsNASDAQ:ADAGAdagene Inc
      04/18/20239:27AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ADAGAdagene Inc
      04/18/20239:17AMGlobeNewswire Inc.Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid TumorsNASDAQ:ADAGAdagene Inc
      03/28/20235:07PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ADAGAdagene Inc
      03/28/20234:30PMGlobeNewswire Inc.Adagene Reports Full Year 2022 Financial Results and Provides Corporate UpdateNASDAQ:ADAGAdagene Inc
      03/14/20236:00PMGlobeNewswire Inc.Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in AprilNASDAQ:ADAGAdagene Inc
      03/05/20237:39PMGlobeNewswire Inc.Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory BoardNASDAQ:ADAGAdagene Inc
       Showing the most relevant articles for your search:NASDAQ:ADAG